Philanthropos

Philanthropos was an early-stage biotechnology company focused on the discovery and development of small molecule inhibitors targeting the PD-1/PD-L1 pathway. Founded by industry veterans, the company aimed to provide oral alternatives to the injectable monoclonal antibodies that dominate the immune checkpoint inhibitor market. Their research centered on identifying small molecules capable of disrupting the protein-protein interaction between PD-1 and its ligand, PD-L1, to restore anti-tumor immune responses. Despite its promising scientific focus, the company remained relatively low-profile and appears to have ceased active operations or transitioned into other entities.